The deal size was increased to $300M in common stock from $250M in common stock. Goldman Sachs acted as lead book running manager for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRTX:
- Mirati Therapeutics reports Q2 EPS ($3.04), consensus ($3.17)
- Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
- Mirati Therapeutics announces $250M common stock offering
- David Meek steps down as CEO of Mirati Therapeutics
- MRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?